From Wikipedia, the free encyclopedia
Jump to: navigation, search
Clinical data
AHFS/ monograph
Routes of
IV only
CAS Registry Number 124584-08-3 N
ATC code C01DX19
PubChem CID: 16134381
DrugBank DB04899 N
ChemSpider 24603113 N
Chemical data
Formula C143H244N50O42S4
Molecular mass 3464 g/mol
 N (what is this?)  (verify)

Nesiritide (Natrecor) is the recombinant form of the 32 amino acid human B-type natriuretic peptide, which is normally produced by the ventricular myocardium. Nesiritide works to facilitate cardiovascular fluid homeostasis through counterregulation of the renin-angiotensin-aldoesterone system, stimulating cyclic guanosine monophosphate, leading to smooth muscle cell relaxation.

Neseritide was believed initially to be beneficial for acute decompensated congestive heart failure. It received approval from the United States' Food and Drug Administration for this purpose in 2001 after initial non-approval. In July 2011 the results of the largest study so far for nesiritide was published in The New England Journal of Medicine; it showed that nesiritide was not associated with a change in mortality or re-hospitalizations.[1]


Nesiritide is only administered intravenously, usually by bolus, followed by IV infusion. For most adults and the elderly, a normal dosage is 2 µg/kg followed by a continuous IV infusion of 0.01 µg/kg/min. This may be increased every three hours for a maximum of 0.03 µg/kg/min.

Side effects[edit]

Common side effects include:

More rare side effects include:


  1. ^ O'Connor (2011). "Effect of nesiritide in patients with acute decompensated heart failure". New England Journal of Medicine 365 (32): 32–43. doi:10.1056/NEJMoa1100171. PMID 21732835. 
  2. ^

Science or Fiction: Use of Nesiritide as a First-Line Agent? John A. Noviasky, Pharm.D., Michael Kelberman, M.D., Karen M. Whalen, B.S., Roy Guharoy, Pharm.D., William Darko, Pharm.D.[1]

External links[edit]